Unique ID issued by UMIN | UMIN000038064 |
---|---|
Receipt number | R000042823 |
Scientific Title | EfficAcy and safety of carboPlatin, etoposide and atezOlizumab for the first-line treatment of patients with extensive-stage smaLL cell lung cancer in the real-wOrld setting. |
Date of disclosure of the study information | 2019/09/24 |
Last modified on | 2021/11/24 12:28:22 |
EfficAcy and safety of carboPlatin, etoposide and atezOlizumab for the first-line treatment of patients with extensive-stage smaLL cell lung cancer in the real-wOrld setting.
APOLLO study
EfficAcy and safety of carboPlatin, etoposide and atezOlizumab for the first-line treatment of patients with extensive-stage smaLL cell lung cancer in the real-wOrld setting.
APOLLO study
Japan |
Small cell lung cancer
Pneumology |
Malignancy
YES
To investigate the efficacy and safety of combination carboplatin / etoposide / atezolizumab combination therapy for advanced small cell lung cancer patients in clinical practice in Japan, and the clinical outcome gap between eligible and ineligible patients for chemoimmunotherapy trial
Safety,Efficacy
6 months-PFS
Overall survival
Progression free survival
Time to treatment failure
Objective response rate
Safety(severe toxicity)
The difference of clinical outcomes between eligible and ineligible patients for Impower 133 trial
Observational
18 | years-old | <= |
120 | years-old | >= |
Male and Female
Extensive-stage small cell lung cancer
Patients scheduled for carboplatin / etoposide / atezolizumab combination therapy
Patients who are judged by the attending doctor as inappropriate to participate in this clinical research
200
1st name | Hiroaki |
Middle name | |
Last name | Akamatsu |
Wakayama Medical University
Third Department of Internal Medicine
641-8509
811-1, kimiidera, Wakayama
073-441-0619
h-akamat@wakayama-med.ac.jp
1st name | Daichi |
Middle name | |
Last name | Fujimoto |
Kobe city medical center general hospital
Division of Respiratory medicine
650-0047
2-1-1, minatojima-minamimachi, chuo-ku, Kobe
078-302-4321
daichianzen@yahoo.co.jp
Wakayama Medical University
Chugai Pharmaceutical Co., Ltd.
Profit organization
Wakayama medical university
Third Department of Internal Medicine
073-441-0619
daichianzen@yahoo.co.jp
NO
2019 | Year | 09 | Month | 24 | Day |
Unpublished
208
No longer recruiting
2019 | Year | 09 | Month | 20 | Day |
2019 | Year | 09 | Month | 20 | Day |
2019 | Year | 09 | Month | 24 | Day |
2021 | Year | 10 | Month | 30 | Day |
prospective cohort study
2019 | Year | 09 | Month | 20 | Day |
2021 | Year | 11 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042823
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |